CLA: How Supreme Court decision impacts ag biotech
One week ago, the U.S. Supreme Court delivered its opinion in Association for Molecular Pathology v. Myriad Genetics, which impacts patent rights in agricultural and non-agricultural biotechnology.
The Supreme Court decision defined patentable subject matter in the context of biotechnology, finding the isolation of DNA from a genome to be a product of nature, and not a "new and useful...composition of matter" that could be protected under patent law.
At the same time, patent claims relating to what the Court referred to as complementary DNA ("cDNA") were found to be patentable.
While the Supreme Court's decision upheld the patentability of cDNA, the Court's decision regarding isolated DNA is a deviation from past judicial and U.S. Patent and Trademark Office interpretations of patentable subject matter in the U.S.
New and useful advances in biotechnology are important not only for identifying and treating disease, but are also part of the solution for preventing malnutrition and hunger - two of the most prevalent causes of death and illness in our world today.
- Texas fall armyworms out early due to unseasonable rains
- Scout for western bean cutworm, western corn rootworm in Ohio
- AgSense releases iPad version of its WagNet Mobile app
- Ag markets posted divergent moves again Thursday
- Ag markets remained mixed at midsession Thursday
- Be wary of wheat quality after wet weather
- Don’t link bird decline and use of neonicotinoids
- Solar energy jobs increase, wind power decrease
- Comments end for Enlist Duo but not the fight
- Commentary: Setting the record straight on 'Waters of the U.S.'
- Setting the record straight on 'Waters of the U.S.'
- Look at fertilizer pricing 2013 vs. 2014